Prior studies have shown that PL’s novel proteoglycan (P1) inhibits colorectal cancer by boosting the immune response to T cells and IgA, and by disrupting the Reg IV/EGFR/Akt signaling pathway. This evidence concerns the gene CD79A and colorectal cancer.